Top

Published in:

01-12-2012

Genes associate with abnormal bone cell activity in bone metastasis

Author: G. David Roodman

Published in: Cancer and Metastasis Reviews | Issue 3-4/2012

Abstract

Bone is one of the most frequent sites of metastasis in patients with malignancies. Up to 90 % of patients with multiple myeloma, and 60 % to 75 % patients with prostate cancer and breast cancer develop bone metastasis at the later stages of their diseases. Bone metastases are responsible for tremendous morbidity in patients with cancer, including severe bone pain, pathologic fractures, spinal cord and nerve compression syndromes, life-threatening hypercalcemia, and increased mortality. Multiple factors produced by tumor cells or produced by the bone marrow microenvironment in response to tumor cells play important roles in activation of osteoclastic bone resorption and modulation of osteoblastic activity in patients with bone metastasis. In this chapter, we will review the genes that play important roles in bone destruction, tumor growth, and osteoblast activity in bone metastasis and discuss the potential therapies targeting the products of these genes to block both bone destruction and tumor growth.

Coleman, R. E. (2000). Management of bone metastases. The Oncologist, 5(6), 463–470.PubMedCrossRef

Coleman, R. E. (2001). Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treatment Reviews, 27, 165–176.PubMedCrossRef

Mundy, G. R. (2002). Metastasis to bone: causes, consequences and therapeutic opportunities. Nature Reviews Cancer, 2, 584–593.PubMedCrossRef

Lipton, A. (2004). Pathophysiology of bone metastases: how this knowledge may lead to therapeutic intervention. Journal of Supportive Oncology, 2(3), 205–213. discussion 213–214, 216–217, 219–220.PubMed

Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A., Mackey, J., Apffelstaedt, J., Hussein, M. A., Coleman, R. E., Reitsma, D. J., Chen, B. L., & Seaman, J. J. (2003). Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer, 98(8), 1735–1744.PubMedCrossRef

Chirgwin, J. M., & Guise, T. A. (2000). Molecular mechanisms of tumor–bone interactions in osteolytic metastases. Critical Reviews in Eukaryotic Gene Expression, 10(2), 159–178.PubMedCrossRef

Taube, T., Elomaa, I., Blomqvist, C., et al. (1994). Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer. Bone, 15(2), 161–166.PubMedCrossRef

Boyde A, Maconnachie E, Reid SA, et al. (1986). Scanning electron microscopy in bone pathology: review of methods, potential and applications. Scan Electron Microsc (Pt 4), 1537–1554.

Fowler, J. A., Edwards, C. M., & Croucher, P. I. (2011). Tumor-host cell interactions in the bone disease of myeloma. Molecular mechanisms of breast cancer metastases to bone. Bone, 48(1), 121–128.PubMedCrossRef

10.

Guise, T. A., Kozlow, W. M., Heras-Herzig, A., Padalecki, S. S., Yin, J. J., & Chirgwin, J. M. (2005). Molecular mechanisms of breast cancer metastases to bone. Clinical Breast Cancer, 5(Suppl(2)), S46–S53.PubMedCrossRef

11.

Roodman, G. D. (2004). Mechanisms of bone metastasis. The New England Journal of Medicine, 350(16), 1655–1664.PubMedCrossRef

12.

Cackowski, F. C., Anderson, J. L., Patrene, K. D., Choksi, R. J., Shapiro, S. D., Windle, J. J., Blair, H. C., & Roodman, G. D. (2010). Osteoclasts are important for bone angiogenesis. Blood, 115(1), 140–149.PubMedCrossRef

13.

Lacey, D. L., Timms, E., Tan, H. L., et al. (1998). Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 93(2), 165–176.PubMedCrossRef

14.

Dougall, W. C., Glaccum, M., Charrier, K., et al. (1999). RANK is essential for osteoclast and lymph node development. Genes & Development, 13(18), 2412–2424.CrossRef

15.

Sezer, O., Heider, U., Jakob, C., et al. (2002). Human bone marrow myeloma cells express RANKL. Journal of Clinical Oncology, 20(1), 353–354.PubMed

16.

Huang, L., Cheng, Y. Y., Chow, L. T. C., Zheng, M. H., & Kumta, S. M. (2002). Tumour cells produce receptor activator of NF-κB ligand (RANKL) in skeletal metastases. J Clin Path, 55(11), 877–878.PubMedCrossRef

17.

Hofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D. L., Boyle, W. J., & Riggs, B. L. (2000). The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. Journal of Bone and Mineral Research, 15(1), 2–12.PubMedCrossRef

18.

Fuller, K., Wong, B., Fox, S., Choi, Y., & Chambers, T. J. (1998). TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. The Journal of Experimental Medicine, 188(5), 997–1001.PubMedCrossRef

19.

Roodman, G. D. (1999). Cell biology of the osteoclast. Experimental Hematology, 27(8), 1229–1241.PubMedCrossRef

20.

Tsukii, K., Shima, N., Mochizuki, S., et al. (1998). Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha, 25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone. Biochemical and Biophysical Research Communications, 246(2), 337–341.PubMedCrossRef

21.

Hofbauer, L. C., Neubauer, A., & Heufelder, A. E. (2001). Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer, 92(3), 460–470.PubMedCrossRef

22.

Feng, X. (2005). RANKing intracellular signaling in osteoclasts. IUBMB Life, 57(6), 389–395.PubMedCrossRef

23.

Santos, V. R., Lima, J. A., Gonçalves, T. E., Bastos, M. F., Figueiredo, L. C., Shibli, J. A., & Duarte, P. M. (2010). Receptor activator of nuclear factor-kappa B ligand/osteoprotegerin ratio in sites of chronic periodontitis of subjects with poorly and well-controlled type 2 diabetes. Journal of Periodontology, 81(10), 1455–1465.PubMedCrossRef

24.

Goranova-Marinova, V., Goranov, S., Pavlov, P., & Tzvetkova, T. (2007). Serum levels of OPG, RANKL and RANKL/OPG ratio in newly-diagnosed patients with multiple myeloma. Clinical Correlations. Haematologica, 92(7), 1000–1001.CrossRef

25.

Terpos, E., Szydlo, R., Apperley, J. F., Hatjiharissi, E., Politou, M., Meletis, J., Viniou, N., Yataganas, X., Goldman, J. M., & Rahemtulla, A. (2003). Soluble receptor activator of nuclear factor KB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood, 102(3), 1064–1069.

26.

Canon, J., Bryant, R., Roudier, M., Osgood, T., Jones, J., Miller, R., Coxon, A., Radinsky, R., & Dougall, W. C. (2010). Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis. Bone, 46(6), 1613–1619.PubMedCrossRef

27.

Canon, J. R., Roudier, M., Bryant, R., Morony, S., Stolina, M., Kostenuik, P. J., & Dougall, W. C. (2008). Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clinical & Experimental Metastasis, 25(2), 119–129.CrossRef

28.

Tannehill-Gregg, S. H., Levine, A. L., Nadella, M. V., Iguchi, H., & Rosol, T. J. (2006). The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice. Clinical & Experimental Metastasis, 23(1), 19–31.CrossRef

29.

Gonzalez-Suarez, E., Jacob, A. P., Jones, J., Miller, R., Roudier-Meyer, M. P., Erwert, R., Pinkas, J., Branstetter, D., & Dougall, W. C. (2010). RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature, 468(7320), 103–107.PubMedCrossRef

30.

Azim, H., Michiels, S., Bedard, P. L., Singhal, S. K., Criscitiello, C., Ignatiadis, M., Haibe-Kains, B., Piccart, M. J., Sotiriou, C., & Loi, S. (2012). Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res, 18, 1341–1351.PubMedCrossRef

31.

Tang, Z. N., Zhang, F., Tang, P., Qi, X. W., & Jiang, J. (2011). RANKL-induced migration of MDA-MB-231 human breast cancer cells via Src and MAPK activation. Oncology Reports, 26(5), 1243–1250. doi:10.3892/or.11.1368.PubMed

32.

Jones, D. H., Nakashima, T., Sanchez, O. H., Kozieradzki, I., Komarova, S. V., Sarosi, I., Morony, S., Rubin, E., Sarao, R., Hojilla, C. V., Komnenovic, V., Kong, Y. Y., Schreiber, M., Dixon, S. J., Sims, S. M., Khokha, R., Wada, T., & Penninger, J. M. (2006). Regulation of cancer cell migration and bone metastasis by RANKL. Nature, 440(7084), 692–696.PubMedCrossRef

33.

Stopeck, A. T., Lipton, A., Body, J. J., Steger, G. G., Tonkin, K., de Boer, R. H., Lichinitser, M., Fujiwara, Y., Yardley, D. A., Viniega, M., Fan, M., Jiang, Q., Dansey, R., Jun, S., & Braun, A. (2010). Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized double-blind study. Journal of Clinical Oncology, 28(35), 5123–5129.CrossRef

34.

Fizazi, K., Carducci, M., Smith, M., Damião, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., Jiang, Q., Tadros, S., Dansey, R., & Goessl, C. (2011). Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study. Lancet, 337(9768), 813–822.CrossRef

35.

Henry, D. H., Costa, L., Goldwasser, F., Hirsh, V., Hungria, V., Prausova, J., Scagliotti, G. V., Sleeboom, H., Spencer, A., Vadhan-Raj, S., von Moos, R., Willenbacher, W., Woll, P. J., Wang, J., Jiang, Q., Jun, S., Dansey, R., & Yeh, H. (2011). Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Journal of Clinical Oncology, 29(9), 1125–1132.PubMedCrossRef

36.

Choi, S. J., Cruz, J. C., Craig, F., et al. (2000). Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood, 96(2), 671–675.PubMed

37.

Han, J. H., Choi, S. J., Kurihara, N., et al. (2001). Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood, 97(11), 3349–3353.PubMedCrossRef

38.

Choi, S. J., Oba, Y., Gazitt, Y., et al. (2001). Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. The Journal of Clinical Investigation, 108(12), 1833–1841.PubMed

39.

Oyajobi, B. O., Franchin, G., Williams, P. J., et al. (2003). Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood, 102(1), 311–319.PubMedCrossRef

40.

Vallet, S., Raje, N., Ishitsuka, K., Hideshima, T., Podar, K., Chhetri, S., Pozzi, S., Breitkreutz, I., Kiziltepe, T., Yasui, H., Ocio, E. M., Shiraishi, N., Jin, J., Okawa, Y., Ikeda, H., Mukherjee, S., Vaghela, N., Cirstea, D., Ladetto, M., Boccadoro, M., & Anderson, K. C. (2007). MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood, 110(10), 3744–3752.PubMedCrossRef

41.

Oba, Y., Lee, J. W., Ehrlich, L. A., Chung, H. Y., Jelinek, D. F., Callander, N. S., Horuk, R., Choi, S. J., & Roodman, G. D. (2005). MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Experimental Hematology, 33(3), 272–278.PubMedCrossRef

42.

Lentzsch, S., Chatterjee, M., Gries, M., Bommert, K., Gollasch, H., Dörken, B., & Bargou. (2004). RC PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells. Leukemia, 18(11), 1883–1890.PubMedCrossRef

43.

Roussou, M., Tasidou, A., Dimopoulos, M. A., Kastritis, E., Migkou, M., Christoulas, D., Gavriatopoulou, M., Zagouri, F., Matsouka, C., Anagnostou, D., & Terpos, E. (2009). Increased expression of macrophage inflammatory protein-1alpha on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma. Leukemia, 23(11), 2177–2181.PubMedCrossRef

44.

Terpos, E., Politou, M., Szydlo, R., Goldman, J. M., Apperley, J. F., & Rahemtulla. (2003). A Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. British Journal of Haematology, 123(1), 106–109.PubMedCrossRef

45.

Cross, N. A., Hillman, L. S., & Forte, L. R. (1998). The effects of calcium supplementation, duration of lactation, and time of day on concentrations of parathyroid hormone-related protein in human milk: a pilot study. Journal of Human Lactation, 14(2), 111–117.PubMedCrossRef

46.

Guise, T. A. (2000). Molecular mechanisms of osteolytic bone metastases. Cancer, 88(12 Suppl), 2892–2898.PubMedCrossRef

47.

Kremer, R., Li, J., Camirand, A., & Karaplis, A. C. (2011). Parathyroid hormone related protein (PTHrP) in tumor progression. Advances in Experimental Medicine and Biology, 720, 145–160.PubMedCrossRef

48.

Yin, J. J., Selander, K., Chirgwin, J. M., Dallas, M., Grubbs, B. G., Wieser, R., Massagué, J., Mundy, G. R., & Guise, T. A. (1999). TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. The Journal of Clinical Investigation, 103(2), 197–206.PubMedCrossRef

49.

Guise, T. A., Yin, J. J., Taylor, S. D., Kumagai, Y., Dallas, M., Boyce, B. F., Yoneda, T., & Mundy, G. R. (1996). Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. The Journal of Clinical Investigation, 98(7), 1544–1549.PubMedCrossRef

50.

Tan, A. R., Alexe, G., & Reiss, M. (2008). Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer? Breast Cancer Research and Treatment, 115(3), 453–495.PubMedCrossRef

51.

Jung, Y., Wang, J., Song, J., et al. (2007). Annexin II expressed by osteoblasts andendothelial cells regulates stem cell adhesion, homing, and engraftment following transplantation. Blood, 110(1), 82–90.PubMedCrossRef

52.

Rescher, U., & Gerke, V. (2004). Annexins-unique membrane binding proteins with diverse functions. Journal of Cell Science, 117(Pt 13), 2631–2639.PubMedCrossRef

53.

Waisman, D. M. (1995). Annexin II tetramer: structure and function. Mol Cell Biochem, 149–150, 301–322.PubMedCrossRef

54.

Lu, G., Maeda, H., Reddy, S. V., et al. (2006). Cloning and characterization of the annexin II receptor on human marrow stromal cells. Journal of Biological Chemistry, 281(41), 30542–30550.PubMedCrossRef

55.

Shiozawa, Y., Havens, A. M., Jung, Y., et al. (2008). Annexin II/Annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer. Journal of Cellular Biochemistry, 105(2), 370–380.PubMedCrossRef

56.

Li, F., Chung, H., Reddy, S. V., et al. (2005). Annexin II stimulates RANKL expression through MAPK. Journal of Bone and Mineral Research, 20(7), 1161–1167.PubMedCrossRef

57.

Takahashi, S., Reddy, S. V., Chirgwin, J. M., et al. (1994). Cloning and identification of annexin II as an autocrine/paracrine factor that increases osteoclast formation and bone resorption. Journal of Biological Chemistry, 269(46), 28696–28701.PubMed

58.

Claudio, J. O., Masih-Khan, E., Tang, H., et al. (2002). A molecular compendium of genes expressed in multiple myeloma. Blood, 100(6), 2175–2186.PubMedCrossRef

59.

Bao, H., Jiang, M., Zhu, M., Sheng, F., Ruan, J., & Ruan, C. (2009). Overexpression of Annexin II affects the proliferation, apoptosis, invasion and production of proangiogenic factors in multiple myeloma. International Journal of Hematology, 90(2), 177–185.PubMedCrossRef

60.

D’Souza, S., Kurihara, N., Shiozawa, Y., Joseph, J., Taichman, R., Galson, D. L., & Roodman, G. D. (2012). Annexin II interactions with the annexin II receptor enhance multiple myeloma cell adhesion and growth in the bone marrow microenvironment. Blood, 119, 1888–1896.PubMedCrossRef

61.

Lee, J. W., Chung, H. Y., Ehrlich, L. A., et al. (2004). IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood, 103(6), 2308–2315.PubMedCrossRef

62.

Rebecca Silbermann, Marina Bolzoni, Paola Storti, Benedetta Dalla Palma, Sabrina Bonomini, Judy Anderson, G. David Roodman, and Nicola Giuliani. (2011). Bone marrow monocyte/macrophage derived activin A mediates the osteoclastogenic effects of IL-3 in myeloma. Blood (ASH Annual Meeting Abstracts) 118: 3933.

63.

Cheung, W. C., & Van Ness, B. (2002). Distinct IL-6 signal transduction leads to growth arrest and death in B cells or growth promotion and cell survival in myeloma cells. Leukemia, 16(6), 1182–1188.PubMedCrossRef

64.

de la Mata, J., Uy, H. L., Guise, T. A., Story, B., Boyce, B. F., Mundy, G. R., & Roodman, G. D. (1995). Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. The Journal of Clinical Investigation, 95(6), 2846–2852.PubMedCrossRef

65.

Gupta, D., Treon, S. P., Shima, Y., Hideshima, T., Podar, K., Tai, Y. T., Lin, B., Lentzsch, S., Davies, F. E., Chauhan, D., Schlossman, R. L., Richardson, P., Ralph, P., Wu, L., Payvandi, F., Muller, G., Stirling, D. I., & Anderson, K. C. (2001). Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia, 15(12), 1950–1961.PubMedCrossRef

66.

Riancho, J. A., & Mundy, G. R. (1995). The role of cytokines and growth factors as mediators of the effects of systemic hormones at the bone local level. Critical Reviews in Eukaryotic Gene Expression, 5(3–4), 193–217.PubMedCrossRef

67.

Raje, N., & Roodman, G. D. (2011). Advances in the biology and treatment of bone disease in multiple myeloma. Clinical Cancer Research, 17(6), 1278–1286.PubMedCrossRef

68.

Li, X., Pennisi, A., & Yaccoby, S. (2008). Role of decorin in the antimyeloma effects of osteoblasts. Blood, 112(1), 159–168.PubMedCrossRef

69.

Yang, X., & Karsenty, G. (2002). Transcription factors in bone: developmental and pathological aspects. Trends in Molecular Medicine, 8, 340.PubMedCrossRef

70.

Roodman, G. D. (2011). Osteoblast function in myeloma. Bone, 48(1), 135–140.PubMedCrossRef

71.

Tian, E., Zhan, F., Walker, R., et al. (2003). The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. The New England Journal of Medicine, 349(26), 2483–2494.PubMedCrossRef

72.

Yaccoby, S., Ling, W., Zhan, F., Walker, R., Barlogie, B., & Shaughnessy, J. D., Jr. (2007). Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood, 109(5), 2106–2111.PubMedCrossRef

73.

Fulciniti, M., Tassone, P., Hideshima, T., et al. (2009). Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood, 114(2), 371–379.PubMedCrossRef

74.

Oshima, T., Abe, M., Asano, J., et al. (2005). Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood, 106(9), 3160–3165.PubMedCrossRef

75.

Ehrlich, L. A., Chung, H. Y., Ghobrial, I., et al. (2005). IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood, 106(4), 1407–1414.PubMedCrossRef

76.

Giuliani, N., Colla, S., Morandi, F., et al. (2005). Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood, 106(7), 2472–2483.PubMedCrossRef

77.

Hjorth-Hansen, H., Seifert, M. F., Börset, M., Aarset, H., Ostlie, A., Sundan, A., & Waage, A. (1999). Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice. Journal of Bone and Mineral Research, 14(2), 256–263.PubMedCrossRef

78.

Rokstad, A. M., Holtan, S., Strand, B., Steinkjer, B., Ryan, L., Kulseng, B., & Skjåk-Braek, G. (2002). Microencapsulation of cells producing therapeutic proteins: optimizing cell growth and secretion. TCell Transplant, 11(4), 313–324.

79.

Kawasaki, T., Niki, Y., Miyamoto, T., Horiuchi, K., Matsumoto, M., Aizawa, M., & Toyama, Y. (2010). The effect of timing in the administration of hepatocyte growth factor to modulate BMP-2-induced osteoblast differentiation. Biomaterials, 31(6), 1191–1198.PubMedCrossRef

80.

Standal, T., Abildgaard, N., Fagerli, U. M., Stordal, B., Hjertner, O., Borset, M., & Sundan, A. (2007). HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood, 109(7), 3024–3030.PubMed

81.

Hideshima, T., Chauhan, D., Podar, K., Schlossman, R. L., Richardson, P., & Anderson, K. C. (2001). Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Seminars in Oncology, 28(6), 607–612.PubMedCrossRef

82.

Zhao, L., Huang, J., Zhang, H., Wang, Y., Matesic, L. E., Takahata, M., Awad, H., Chen, D., & Xing, L. (2011). Tumor necrosis factor inhibits mesenchymal stem cell differentiation into osteoblasts via the ubiquitin E3 ligase Wwp1. Stem Cells, 29(10), 1601–1610. doi:10.1002/stem.703.PubMedCrossRef

83.

Olfa, G., Christophe, C., Philippe, L., Romain, S., Khaled, H., Pierre, H., Odile, B., & Jean-Christophe, D. (2010). RUNX2 regulates the effects of TNFalpha on proliferation and apoptosis in SaOs-2 cells. Bone, 46(4), 901–910.PubMedCrossRef

84.

Vallet, S., Mukherjee, S., Vaghela, N., Hideshima, T., Fulciniti, M., Pozzi, S., Santo, L., Cirstea, D., Patel, K., Sohani, A. R., Guimaraes, A., Xie, W., Chauhan, D., Schoonmaker, J. A., Attar, E., Churchill, M., Weller, E., Munshi, N., Seehra, J. S., Weissleder, R., Anderson, K. C., Scadden, D. T., & Raje, N. (2010). Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proceedings of the National Academy of Sciences of the United States of America, 107(11), 5124–5129.PubMedCrossRef

85.

Chantry, A. D., Heath, D., Mulivor, A. W., Pearsall, S., Baud'huin, M., Coulton, L., Evans, H., Abdul, N., Werner, E. D., Bouxsein, M. L., Key, M. L., Seehra, J., Arnett, T. R., Vanderkerken, K., & Croucher, P. (2010). Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. Journal of Bone and Mineral Research, 25(12), 2633–2646. doi:10.1002/jbmr.142. Erratum in: J Bone Miner Res, 26(2), 439.PubMedCrossRef

86.

Lotinun, S., Pearsall, R. S., Davies, M. V., Marvell, T. H., Monnell, T. E., Ucran, J., Fajardo, R. J., Kumar, R., Underwood, K. W., Seehra, J., Bouxsein, M. L., & Baron, R. (2010). A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys. Bone, 46(4), 1082–1088.PubMedCrossRef

87.

Abdulkadyrov KM, Salogub GN, Khuazheva NK, Woolf R, Haltom E, Borgstein NG, Knight R, Renshaw G, Yang Y, Sherman ML. (2009). ACE-011, a Soluble Activin Receptor Type Iia IgG-Fc Fusion Protein, Increases Hemoglobin (Hb) and Improves Bone Lesions in Multiple Myeloma Patients Receiving Myelosuppressive Chemotherapy: Preliminary Analysis, American Society of Hematology (ASH) Meeting, Abstract 749.

88.

Brunetti, G., Oranger, A., Mori, G., Specchia, G., Rinaldi, E., Curci, P., Zallone, A., Rizzi, R., Grano, M., & Colucci, S. (2011). Sclerostin is overexpressed by plasma cells from multiple myeloma patients. Ann NY Acad Sci, 1237, 19–23. doi:10.1111/j.1749-6632.2011.06196.x.PubMedCrossRef

89.

Mendoza-Villanueva, D., Zeef, L., & Shore, P. (2011). Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFβ-dependent expression of the Wnt antagonist, sclerostin. Breast Cancer Research, 13(5), R106.PubMedCrossRef

90.

van Lierop, A. H., Hamdy, N. A., Hamersma, H., van Bezooijen, R. L., Power, J., Loveridge, N., & Papapoulos, S. E. (2011). Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. Journal of Bone and Mineral Research, 26(12), 2804–2811. doi:10.1002/jbmr.474.PubMedCrossRef

91.

Paszty, C., Turner, C. H., & Robinson, M. K. (2010). Sclerostin: a gem from the genome leads to bone-building antibodies. Journal of Bone and Mineral Research, 25(9), 1897–1904.PubMedCrossRef

92.

Terpos, E., Christoulas, D., Katodritou, E., Bratengeier, C., Gkotzamanidou, M., Michalis, E., Delimpasi, S., Pouli, A., Meletis, J., Kastritis, E., Zervas, K., & Dimopoulos, M. A. (2011). Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy. International Journal of Cancer. doi:10.1002/ijc.27342.

93.

D'Souza, S., del Prete, D., Jin, S., Sun, Q., Huston, A. J., Kostov, F. E., Sammut, B., Hong, C. S., Anderson, J. L., Patrene, K. D., Yu, S., Velu, C. S., Xiao, G., Grimes, H. L., Roodman, G. D., & Galson, D. L. (2011). Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease. Blood, 118(26), 6871–6880.PubMedCrossRef

94.

Guise, T. A., Yin, J. J., & Mohammad, K. S. (2003). Role of endothelin-1 in osteoblastic bone metastases. Cancer, 97(3 Suppl), 779–784.PubMedCrossRef

95.

Granchi, S., Brocchi, S., Bonaccorsi, L., Baldi, E., Vinci, M. C., Forti, G., Serio, M., & Maggi, M. (2001). Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens. Prostate, 49(4), 267–277.PubMedCrossRef

96.

Clines, G. A., Mohammad, K. S., Bao, Y., et al. (2007). Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Molecular Endocrinology, 21(2), 486–498.PubMedCrossRef

97.

Yuyama, H., Koakutsu, A., Fujiyasu, N., Tanahashi, M., Fujimori, A., Sato, S., Shibasaki, K., Tanaka, S., Sudoh, K., Sasamata, M., & Miyata, K. (2004). Effects of selective endothelin ET(A) receptor antagonists on endothelin-1-induced potentiation of cancer pain. European Journal of Pharmacology, 492(2–3), 177–182.PubMedCrossRef

98.

Yi, B., Williams, P. J., Niewolna, M., et al. (2002). Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Research, 62(3), 917–923.PubMed

99.

Dai, J., Keller, J., Zhang, J., et al. (2005). Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Research, 65(18), 8274–8285.PubMedCrossRef

100.

Hall, C. L., Bafico, A., Dai, J., et al. (2005). Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Research, 65(17), 7554–7560.PubMed

101.

Achbarou, A., Kaiser, S., Tremblay, G., et al. (1994). Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Research, 54(9), 2372–2377.PubMed

Title: Genes associate with abnormal bone cell activity in bone metastasis
Author: G. David Roodman
Publication date: 01-12-2012
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 3-4/2012
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-012-9372-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3-4/2012

Pharmacological strategies to spare normal tissues from radiation damage: useless or overlooked therapeutics?

Transcription factor PROX1: its role in development and cancer

Raf kinase inhibitor protein (RKIP) in cancer

Molecular characterization of circulating tumor cells in breast cancer: challenges and promises for individualized cancer treatment

Growth factor signaling in metastasis: current understanding and future opportunities

Insights into the biology and prevention of tumor metastasis provided by the Nm23 metastasis suppressor gene

Keynote webinar | Spotlight on antibody–drug conjugates in cancer